Link to this page
Biological and Environmental Research Ontology
Last uploaded:
December 23, 2022
| Id | http://purl.obolibrary.org/obo/NCIT_C95712
http://purl.obolibrary.org/obo/NCIT_C95712
|
|---|---|
| Preferred Name | Nesvacumab |
| Definitions |
A fully human monoclonal antibody directed against angiopoietin 2 (ANG2) with potential antiangiogenic and antineoplastic activities. Nesvacumab binds to ANG2 and interferes with the interaction between Ang2 and its receptor TEK tyrosine kinase (Tie2), which may inhibit tumor cell angiogenesis and tumor cell proliferation. ANG2 is upregulated in a variety of cancer cell types and plays a crucial role in angiogenesis.
|
| Type | http://www.w3.org/2002/07/owl#Class |
All Properties
| definition | A fully human monoclonal antibody directed against angiopoietin 2 (ANG2) with potential antiangiogenic and antineoplastic activities. Nesvacumab binds to ANG2 and interferes with the interaction between Ang2 and its receptor TEK tyrosine kinase (Tie2), which may inhibit tumor cell angiogenesis and tumor cell proliferation. ANG2 is upregulated in a variety of cancer cell types and plays a crucial role in angiogenesis. |
|---|---|
| prefLabel | Nesvacumab
|
| label | Nesvacumab
|
| NCI_META_CUI | CL428177
|
| PDQ_Closed_Trial_Search_ID | 693224
|
| code | C95712
|
| Has_Target | |
| prefixIRI | NCIT:C95712
|
| in_subset | |
| Preferred_Name | Nesvacumab
|
| FDA_UNII_Code | WX8293WGLC
|
| Contributing_Source | FDA
|
| Maps_To | Nesvacumab
|
| CAS_Registry | 1296818-77-3
|
| NCI_Drug_Dictionary_ID | 693224
|
| type | |
| Is_Value_For_GDC_Property | |
| subClassOf | |
| PDQ_Open_Trial_Search_ID | 693224
|
| Semantic_Type |
Pharmacologic Substance
Immunologic Factor
|
| Delete | Subject | Author | Type | Created |
|---|---|---|---|---|
| No notes to display |